SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [41] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Suzanne V. Arnold
    Fengming Tang
    Andrew Cooper
    Hungta Chen
    Marilia B. Gomes
    Wolfgang Rathmann
    Iichiro Shimomura
    Jiten Vora
    Hirotaka Watada
    Kamlesh Khunti
    Mikhail Kosiborod
    BMC Endocrine Disorders, 22
  • [42] Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach
    Bronden, Andreas
    Christensen, Mikkel Bring
    Glintborg, Dorte
    Snorgaard, Ole
    Kofoed-Enevoldsen, Allan
    Madsen, Gitte Krogh
    Toft, Katja
    Kristensen, Jette Kolding
    Hojlund, Kurt
    Hansen, Troels Krarup
    Sondergaard, Esben
    Hansen, Katrine Bagge
    DIABETIC MEDICINE, 2023, 40 (08)
  • [43] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [44] Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
    Nincevic, Vjera
    Kolaric, Tea Omanovic
    Roguljic, Hrvoje
    Kizivat, Tomislav
    Smolic, Martina
    Curcic, Ines Bilic
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
  • [45] GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
    Karagiannis, Thomas
    Tsapas, Apostolos
    Athanasiadou, Eleni
    Avgerinos, Ioannis
    Liakos, Aris
    Matthews, David R.
    Bekiari, Eleni
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 174
  • [46] SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
    Ahmed-Sarwar, Nabila
    Nagel, Angela K.
    Leistman, Samantha
    Heacock, Kevin
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (09) : 791 - 796
  • [47] GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
    Santulli, Gaetano
    Mone, Pasquale
    Varzideh, Fahimeh
    FUTURE CARDIOLOGY, 2025, 21 (01) : 5 - 8
  • [48] Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study
    Chang, Kai-Cheng
    Kuo, Fan-Chi
    Yang, Chen-Yi
    Yang, Chun-Ting
    Ou, Huang-Tz
    Kuo, Shihchen
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [49] SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
    Bloomgarden, Zachary T.
    Handelsman, Yehuda
    ENDOCRINE PRACTICE, 2015, 21 (12) : 1442 - 1444
  • [50] Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
    Santos, Leyna Leite
    Camello De Lima, Fernando Jose
    De Sousa-Rodrigues, Celio Fernando
    Barbosa, Fabiano Timbo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (07): : 636 - 641
12345